BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014;40:692-700. [PMID: 24656602 DOI: 10.1016/j.ctrv.2014.03.002] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Sabbagh P, Mohammadnia-afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis 2019;38:55-66. [DOI: 10.1007/s10096-018-3414-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, Sun Y, Gu J. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits. Gastroenterology 2016;150:1183-1195.e16. [PMID: 26855187 DOI: 10.1053/j.gastro.2016.01.034] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
3 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 166] [Article Influence: 15.4] [Reference Citation Analysis]
4 Sun R, Wang X, Zhu H, Mei H, Wang W, Zhang S, Huang J. Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. Oncotarget 2014;5:12398-409. [PMID: 25362357 DOI: 10.18632/oncotarget.2643] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
5 Feng J, Qin S. The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model. Onco Targets Ther 2018;11:3047-57. [PMID: 29872316 DOI: 10.2147/OTT.S159935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wang H, Jiang Z, Chen H, Wu X, Xiang J, Peng J. MicroRNA-495 Inhibits Gastric Cancer Cell Migration and Invasion Possibly via Targeting High Mobility Group AT-Hook 2 (HMGA2). Med Sci Monit 2017;23:640-8. [PMID: 28159956 DOI: 10.12659/msm.898740] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
7 Marano L, Polom K, Bartoli A, Spaziani A, De Luca R, Lorenzon L, Di Martino N, Marrelli D, Roviello F, Castagnoli G. Oncologic Effectiveness and Safety of Bursectomy in Patients with Advanced Gastric Cancer: A Systematic Review and Updated Meta-Analysis. Journal of Investigative Surgery 2018;31:529-38. [DOI: 10.1080/08941939.2017.1355942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Roviello G, Corona SP, Multari AG, Petrioli R, Rosellini P, Aieta M. Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. Anti-Cancer Drugs 2019;30:745-8. [DOI: 10.1097/cad.0000000000000789] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Invest New Drugs 2019;37:524-30. [DOI: 10.1007/s10637-019-00725-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Li P, Hu J, Shi B, Tie J. Baicalein enhanced cisplatin sensitivity of gastric cancer cells by inducing cell apoptosis and autophagy via Akt/mTOR and Nrf2/Keap 1 pathway. Biochem Biophys Res Commun 2020;531:320-7. [PMID: 32800561 DOI: 10.1016/j.bbrc.2020.07.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Gu ML, Zhou XX, Ren MT, Shi KD, Yu MS, Jiao WR, Wang YM, Zhong WX, Ji F. Blockage of ETS homologous factor inhibits the proliferation and invasion of gastric cancer cells through the c-Met pathway. World J Gastroenterol 2020; 26(47): 7497-7512 [PMID: 33384550 DOI: 10.3748/wjg.v26.i47.7497] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang JK, Wang WJ, Cai HY, Du BB, Mai P, Zhang LJ, Ma W, Hu YG, Feng SF, Miao GY. MFAP2 promotes epithelial-mesenchymal transition in gastric cancer cells by activating TGF-β/SMAD2/3 signaling pathway. Onco Targets Ther 2018;11:4001-17. [PMID: 30034240 DOI: 10.2147/OTT.S160831] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
13 Giroux V, Rustgi AK. Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence. Nat Rev Cancer. 2017;17:594-604. [PMID: 28860646 DOI: 10.1038/nrc.2017.68] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 18.2] [Reference Citation Analysis]
14 Li Y, Gao W, Ma Y, Zhu G, Chen F, Qu H. Dual targeting of survivin and X-linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC-27 cells. Oncol Lett 2018;16:3489-98. [PMID: 30127953 DOI: 10.3892/ol.2018.9081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Min L, Ruan Y, Shen Z, Jia D, Wang X, Zhao J, Sun Y, Gu J. Overexpression of Ras-GTPase-activating protein SH3 domain-binding protein 1 correlates with poor prognosis in gastric cancer patients. Histopathology 2015;67:677-88. [PMID: 25809930 DOI: 10.1111/his.12695] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
16 Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. Ann Oncol 2019;30:1254-64. [PMID: 31046106 DOI: 10.1093/annonc/mdz143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
17 Balmaña M, Diniz F, Feijão T, Barrias CC, Mereiter S, Reis CA. Analysis of the Effect of Increased α2,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib. Int J Mol Sci 2020;21:E722. [PMID: 31979110 DOI: 10.3390/ijms21030722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zhang L, Pan K, Zuo Z, Ye F, Cao D, Peng Y, Tang T, Li X, Zhou S, Duan L. LINC01133 hampers the development of gastric cancer through increasing somatostatin via binding to microRNA-576-5p. Epigenomics 2021;13:1205-19. [PMID: 34318683 DOI: 10.2217/epi-2020-0377] [Reference Citation Analysis]
19 Pfeiffer P, Qvortrup C, Krogh M, Schoennemann K, Vestermark LW, Jensen HA, Bjerregaard JK. S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. Acta Oncol 2017;56:46-51. [PMID: 27911128 DOI: 10.1080/0284186X.2016.1257865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Wang Y, Appiah-Kubi K, Lan T, Wu M, Pang J, Qian H, Tao Y, Jiang L, Wu Y, Chen Y. PKG II inhibits PDGF-BB triggered biological activities by phosphorylating PDGFRβ in gastric cancer cells. Cell Biol Int 2018;42:1358-69. [PMID: 29935031 DOI: 10.1002/cbin.11020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Queirós P, Pinheiro H, Carvalho J, Oliveira P, Gullo I, Carneiro F, Almeida GM, Oliveira C. KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. Virchows Arch 2015;467:383-92. [PMID: 26318594 DOI: 10.1007/s00428-015-1823-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Lin C, Fan H, Chen W, Cui L. Palliative Gastrectomy vs. Gastrojejunostomy for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. Front Surg 2021;8:723065. [PMID: 34901136 DOI: 10.3389/fsurg.2021.723065] [Reference Citation Analysis]
23 Qian H, Appiah-Kubi K, Wang Y, Wu M, Tao Y, Wu Y, Chen Y. The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2018;127:15-28. [PMID: 29891108 DOI: 10.1016/j.critrevonc.2018.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
24 Zhou C, Ma T, Shi M, Xi W, Wu J, Yang C, Zhu Z, Zhang J. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach. Cancer Chemother Pharmacol 2020;85:113-9. [PMID: 31691079 DOI: 10.1007/s00280-019-03982-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol 2015; 21(26): 7954-7969 [PMID: 26185368 DOI: 10.3748/wjg.v21.i26.7954] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
26 Jeung YJ, Lee K, Lee HJ, Kim E, Son MJ, Ahn J, Kim HG, Kim W, Lee HJ, Kim JM, Chung KS. Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer. Cancer Sci 2019;110:1453-63. [PMID: 30729615 DOI: 10.1111/cas.13966] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Osterlund P, Sorbye H, Pfeiffer P, Johnsson A, Rodrigues F, Furneri G. Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy 2016;7:12-22. [DOI: 10.1016/j.jcpo.2015.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, Haffner I, Schierle K, Weirich G, Luber B. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol Oncol 2018;12:441-62. [PMID: 29325228 DOI: 10.1002/1878-0261.12170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
29 Shitara K, Yodo Y, Iino S. A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer. In Vivo 2019;33:933-7. [PMID: 31028219 DOI: 10.21873/invivo.11561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Gao W, Xu J, Wang F, Zhang L, Peng R, Shu Y, Wu J, Tang Q, Zhu Y. Plasma membrane proteomic analysis of human Gastric Cancer tissues: revealing flotillin 1 as a marker for Gastric Cancer. BMC Cancer. 2015;15:367. [PMID: 25948494 DOI: 10.1186/s12885-015-1343-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
31 Rodríguez-de-Santiago E, Hernanz N, Marcos-Prieto HM, de Jorge-Turrión MÁ, Barreiro-Alonso E, Rodríguez-Escaja C, Jiménez-Jurado A, Machado-Volpato N, Pérez-Valle I, García-Prada M, Sierra-Morales M, Ríos León R, Núñez Gómez L, García García-de-Paredes A, Castaño-García A, Foruny-Olcina JR, Peñas-García B, Vázquez-Sequeiros E, Albillos A. A multicentric Spanish study on the characteristics and survival of gastric adenocarcinoma under the age of 60. Gastroenterol Hepatol 2019;42:595-603. [PMID: 31519387 DOI: 10.1016/j.gastrohep.2019.07.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
32 Zou P, Xia Y, Chen T, Zhang J, Wang Z, Chen W, Chen M, Kanchana K, Yang S, Liang G. Selective killing of gastric cancer cells by a small molecule targeting ROS-mediated ER stress activation: ROS INDUCTION CONTRIBUTES TO CANCER TREATMENT. Mol Carcinog 2016;55:1073-86. [DOI: 10.1002/mc.22351] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
33 Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894-904. [PMID: 24950987 DOI: 10.1016/s1470-2045(14)70024-5] [Cited by in Crossref: 174] [Cited by in F6Publishing: 125] [Article Influence: 21.8] [Reference Citation Analysis]
34 Wang H, Meng Q, Ma B. Characterization of the Prognostic m6A-Related lncRNA Signature in Gastric Cancer. Front Oncol 2021;11:630260. [PMID: 33928026 DOI: 10.3389/fonc.2021.630260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Poltronieri-oliveira AB, Madeira FF, Nunes DBSM, Rodrigues GH, Lopes BC, Manoel-caetano FS, Biselli JM, Silva AE. Polymorphisms of miR-196a2 (rs11614913) and miR-605 (rs2043556) confer susceptibility to gastric cancer. Gene Reports 2017;7:154-63. [DOI: 10.1016/j.genrep.2017.04.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
36 Gao YY, Han RB, Wang X, Ge SH, Li HL, Deng T, Liu R, Bai M, Zhou LK, Zhang XY. Change of SPARC expression after chemotherapy in gastric cancer. Cancer Biol Med. 2015;12:33-40. [PMID: 25859409 DOI: 10.7497/j.issn.2095-3941.2014.0023] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
37 Cao W, Li Y, Sun H, Yang C, Zhu J, Xie C, Li X, Wu J, Geng S, Wang L, Sun L, Geng G, Han H, Zhong C. Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway. Front Cell Dev Biol 2021;9:679806. [PMID: 34350176 DOI: 10.3389/fcell.2021.679806] [Reference Citation Analysis]
38 Zhou J, Wu L, Li W, Xu X, Ju F, Yu S, Guo J, Li G, Shi J, Zhou S. Long Noncoding RNA LINC01485 Promotes Tumor Growth and Migration via Inhibiting EGFR Ubiquitination and Activating EGFR/Akt Signaling in Gastric Cancer. Onco Targets Ther 2020;13:8413-25. [PMID: 32904620 DOI: 10.2147/OTT.S257151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Andreuzzi E, Fejza A, Capuano A, Poletto E, Pivetta E, Doliana R, Pellicani R, Favero A, Maiero S, Fornasarig M, Cannizzaro R, Iozzo RV, Spessotto P, Mongiat M. Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis. Matrix Biol Plus 2020;6-7:100029. [PMID: 33543026 DOI: 10.1016/j.mbplus.2020.100029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
40 Wang Z, Yang Y, Cui Y, Wang C, Lai Z, Li Y, Zhang W, Mustonen H, Puolakkainen P, Ye Y, Jiang K, Shen Z, Wang S. Tumor-associated macrophages regulate gastric cancer cell invasion and metastasis through TGFβ2/NF-κB/Kindlin-2 axis. Chin J Cancer Res 2020;32:72-88. [PMID: 32194307 DOI: 10.21147/j.issn.1000-9604.2020.01.09] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
41 Andreuzzi E, Capuano A, Pellicani R, Poletto E, Doliana R, Maiero S, Fornasarig M, Magris R, Colombatti A, Cannizzaro R, Spessotto P, Mongiat M. Loss of Multimerin-2 and EMILIN-2 Expression in Gastric Cancer Associate with Altered Angiogenesis. Int J Mol Sci 2018;19:E3983. [PMID: 30544909 DOI: 10.3390/ijms19123983] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
42 Díaz P, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression. Front Microbiol 2018;9:5. [PMID: 29403459 DOI: 10.3389/fmicb.2018.00005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
43 Avcı N, Ture M, Deligonul A, Cubukcu E, Olmez OF, Sahinturk S, Topak A, Kurt E, Evrensel T, Şahin AB, Yakut T. Association and Prognostic Significance of the Functional -1562C/T Polymorphism in the Promoter Region of MMP-9 in Turkish Patients with Gastric Cancer. Pathol Oncol Res 2015;21:1243-7. [PMID: 26156886 DOI: 10.1007/s12253-015-9950-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
44 Nakajima M, Yoshino S, Kanekiyo S, Maeda N, Sakamoto K, Tsunedomi R, Suzuki N, Takeda S, Yamamoto S, Hazama S, Hoshii Y, Oga A, Itoh H, Ueno T, Nagano H. High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer. Oncol Lett. 2018;15:803-812. [PMID: 29403557 DOI: 10.3892/ol.2017.7418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
45 Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, Jin MM. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Mol Ther Oncolytics 2020;18:587-601. [PMID: 32995483 DOI: 10.1016/j.omto.2020.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 Wang R, Fang D. Detection of phosphatidylserine in the plasma membrane of single apoptotic cells using electrochemiluminescence. RSC Adv 2017;7:12969-72. [DOI: 10.1039/c6ra28031e] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Li C, Tang T, Wang W. Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study. Gastroenterol Res Pract 2020;2020:3232950. [PMID: 32328095 DOI: 10.1155/2020/3232950] [Reference Citation Analysis]
48 Wu JQ, Fan RY, Zhang SR, Li CY, Shen LZ, Wei P, He ZH, He MF. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model. Life Sci 2020;247:117402. [PMID: 32035930 DOI: 10.1016/j.lfs.2020.117402] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
49 Yang M, Jiang N, Cao Q, Ma M, Sun Q. The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1. Biochemical and Biophysical Research Communications 2016;478:1624-9. [DOI: 10.1016/j.bbrc.2016.08.170] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
50 Chen Y, Chen N, Xu J, Wang X, Wei X, Tang C, Duanmu Z, Shi J. Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway in vivo. Aging (Albany NY) 2021;13:20738-47. [PMID: 34453028 DOI: 10.18632/aging.203458] [Reference Citation Analysis]
51 Jung M, Ryu M, Oh DY, Kang M, Zang DY, Hwang IG, Lee K, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo D, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang Y. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 2018;21:819-30. [DOI: 10.1007/s10120-018-0806-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
52 Lordick F. Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis. Nat Rev Clin Oncol 2015;12:7-8. [PMID: 25403941 DOI: 10.1038/nrclinonc.2014.195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
53 Hum M, Tan HJ, Yang Y, Srivastava S, Teh M, Lim YP. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway. FASEB J 2021;35:e21290. [PMID: 33475198 DOI: 10.1096/fj.202000393R] [Reference Citation Analysis]
54 Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D. Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 2016;10:887-92. [PMID: 27376400 DOI: 10.1080/17474124.2016.1209407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
55 Huang L, Zhang X, Wei Z, Xu A. Importance of Examined Lymph Node Number in Accurate Staging and Enhanced Survival in Resected Gastric Adenocarcinoma-The More, the Better? A Cohort Study of 8,696 Cases From the US and China, 2010-2016. Front Oncol 2020;10:539030. [PMID: 33585181 DOI: 10.3389/fonc.2020.539030] [Reference Citation Analysis]
56 Keller S, Kneissl J, Grabher-Meier V, Heindl S, Hasenauer J, Maier D, Mattes J, Winter P, Luber B. Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis. BMC Cancer 2017;17:845. [PMID: 29237412 DOI: 10.1186/s12885-017-3822-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
57 Maguire R, Kotronoulas G, Simpson M, Paterson C. A systematic review of the supportive care needs of women living with and beyond cervical cancer. Gynecologic Oncology 2015;136:478-90. [DOI: 10.1016/j.ygyno.2014.10.030] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
58 Raimúndez E, Keller S, Zwingenberger G, Ebert K, Hug S, Theis FJ, Maier D, Luber B, Hasenauer J. Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines. PLoS Comput Biol 2020;16:e1007147. [PMID: 32119655 DOI: 10.1371/journal.pcbi.1007147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Dai J, Peng T, Yu X. NK6 Homeobox 2 Regulated Gastrokin-2 Suppresses Gastric Cancer Cell Proliferation and Invasion via Akt Signaling Pathway. Cell Biochem Biophys 2021;79:123-31. [PMID: 33009998 DOI: 10.1007/s12013-020-00948-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Zhang C, Zhu Q, Gu J, Chen S, Li Q, Ying L. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin. Biosci Rep 2019;39:BSR20190381. [PMID: 31072916 DOI: 10.1042/BSR20190381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
61 Gambardella V, Fleitas T, Tarazona N, Papaccio F, Huerta M, Roselló S, Gimeno-Valiente F, Roda D, Cervantes A. Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. J Clin Med 2020;9:E3049. [PMID: 32971757 DOI: 10.3390/jcm9093049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Sobhani N, Generali D, Roviello G. PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. EBioMedicine 2017;22:18-9. [PMID: 28688823 DOI: 10.1016/j.ebiom.2017.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
63 Grunberg N, Pevsner-Fischer M, Goshen-Lago T, Diment J, Stein Y, Lavon H, Mayer S, Levi-Galibov O, Friedman G, Ofir-Birin Y, Syu LJ, Migliore C, Shimoni E, Stemmer SM, Brenner B, Dlugosz AA, Lyden D, Regev-Rudzki N, Ben-Aharon I, Scherz-Shouval R. Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles. Cancer Res 2021;81:1639-53. [PMID: 33547159 DOI: 10.1158/0008-5472.CAN-20-2756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
64 Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M. Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. Medicine (Baltimore) 2018;97:e10745. [PMID: 29768350 DOI: 10.1097/MD.0000000000010745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Peng P, Wu W, Zhao J, Song S, Wang X, Jia D, Shao M, Zhang M, Li L, Wang L, Duan F, Zhao R, Yang C, Wu H, Zhang J, Shen Z, Ruan Y, Gu J. Decreased expression of Calpain-9 predicts unfavorable prognosis in patients with gastric cancer. Sci Rep 2016;6:29604. [PMID: 27404891 DOI: 10.1038/srep29604] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
66 Hao LS, Liu Q, Tian C, Zhang DX, Wang B, Zhou DX, Li ZP, Yuan ZX. Correlation and expression analysis of hypoxia-inducible factor 1α, glucose transporter 1 and lactate dehydrogenase 5 in human gastric cancer. Oncol Lett 2019;18:1431-41. [PMID: 31423208 DOI: 10.3892/ol.2019.10457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
67 Lim JY, Kim D, Kim BR, Jun JS, Yeom JS, Park JS, Seo JH, Park CH, Woo HO, Youn HS, Baik SC, Lee WK, Cho MJ, Rhee KH. Vitamin C induces apoptosis in AGS cells via production of ROS of mitochondria. Oncol Lett 2016;12:4270-6. [PMID: 27895802 DOI: 10.3892/ol.2016.5212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
68 Angell HK, Lee J, Kim KM, Kim K, Kim ST, Park SH, Kang WK, Sharpe A, Ogden J, Davenport A, Hodgson DR, Barrett JC, Kilgour E. PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. Oncoimmunology 2019;8:e1544442. [PMID: 30729066 DOI: 10.1080/2162402X.2018.1544442] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
69 Zhou X, Xia Y, Li L, Zhang G. MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2. Cancer Biol Ther. 2015;16:160-169. [PMID: 25561270 DOI: 10.4161/15384047.2014.987523] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
70 Liu Y, Zhang Y, Zhao Y, Gao D, Xing J, Liu H. High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer. Oncol Lett. 2016;12:3825-3835. [PMID: 27895737 DOI: 10.3892/ol.2016.5169] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
71 Capuano A, Andreuzzi E, Pivetta E, Doliana R, Favero A, Canzonieri V, Maiero S, Fornasarig M, Magris R, Cannizzaro R, Mongiat M, Spessotto P. The Probe Based Confocal Laser Endomicroscopy (pCLE) in Locally Advanced Gastric Cancer: A Powerful Technique for Real-Time Analysis of Vasculature. Front Oncol 2019;9:513. [PMID: 31263680 DOI: 10.3389/fonc.2019.00513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Teng F, Xu Z, Chen J, Zheng G, Zheng G, Lv H, Wang Y, Wang L, Cheng X. DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer. Oncol Rep 2018;40:1203-22. [PMID: 29956792 DOI: 10.3892/or.2018.6520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
73 Zhou C, Ji J, Cai Q, Shi M, Chen X, Yu Y, Zhu Z, Zhang J. MTA2 enhances colony formation and tumor growth of gastric cancer cells through IL-11. BMC Cancer 2015;15:343. [PMID: 25929737 DOI: 10.1186/s12885-015-1366-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
74 Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, García-Foncillas J, Candrilli SD, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl) 2020;29:e13213. [PMID: 31883156 DOI: 10.1111/ecc.13213] [Reference Citation Analysis]
75 Jiang H, Pei L, Liu N, Li J, Li Z, Zhang S. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Deliv 2016;23:1379-82. [PMID: 26162024 DOI: 10.3109/10717544.2015.1048491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
76 Qian S, Villarejo-Campos P, García-Olmo D. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications. J Clin Med 2021;10:5050. [PMID: 34768570 DOI: 10.3390/jcm10215050] [Reference Citation Analysis]
77 Yu Y, Li H, Wu C, Li J. Circ_0021087 acts as a miR-184 sponge and represses gastric cancer progression by adsorbing miR-184 and elevating FOSB expression. Eur J Clin Invest 2021;:e13605. [PMID: 34076278 DOI: 10.1111/eci.13605] [Reference Citation Analysis]
78 Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F, Generali D. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372:187-191. [PMID: 26797419 DOI: 10.1016/j.canlet.2016.01.014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 80] [Article Influence: 11.3] [Reference Citation Analysis]
79 Russi S, Verma HK, Laurino S, Mazzone P, Storto G, Nardelli A, Zoppoli P, Calice G, La Rocca F, Sgambato A, Lucci V, Falco G, Ruggieri V. Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells. Int J Mol Sci 2019;20:E3736. [PMID: 31370155 DOI: 10.3390/ijms20153736] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
80 Morais S, Antunes L, Bento MJ, Lunet N. Risk of second primary cancers among patients with a first primary gastric cancer: A population-based study in North Portugal. Cancer Epidemiol 2017;50:85-91. [PMID: 28843176 DOI: 10.1016/j.canep.2017.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
81 Hess S, Bjerring OS, Pfeiffer P, Høilund-Carlsen PF. Personalized Clinical Decision Making in Gastrointestinal Malignancies: The Role of PET. PET Clin 2016;11:273-83. [PMID: 27321031 DOI: 10.1016/j.cpet.2016.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
82 He JQ, Zhang SR, Li DF, Tang JY, Wang YQ, He X, Li YM, Wu H, Zhou M, Jiao J, Xiao PL. Experimental Study on the Effect of a Weifufang on Human Gastric Adenocarcinoma Cell Line BGC-823 Xenografts and PTEN Gene Expression in Nude Mice. Cancer Biother Radiopharm 2020;35:199-207. [PMID: 31976763 DOI: 10.1089/cbr.2019.2906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Zhang Z, Min L, Li H, Chen L, Zhao Y, Liu S, Guo Q, Zhu S, Li P, Zhang S. Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin. Oncogene 2021;40:4552-66. [PMID: 34127813 DOI: 10.1038/s41388-021-01858-7] [Reference Citation Analysis]
84 Duan C, Zhang B, Deng C, Cao Y, Zhou F, Wu L, Chen M, Shen S, Xu G, Zhang S, Duan G, Yan H, Zou X. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo. Tumour Biol 2016;37:10793-804. [PMID: 26874726 DOI: 10.1007/s13277-016-4792-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
85 Morais S, Ferro A, Bastos A, Castro C, Lunet N, Peleteiro B. Trends in gastric cancer mortality and in the prevalence of Helicobacter pylori infection in Portugal. Eur J Cancer Prev 2016;25:275-81. [PMID: 26186469 DOI: 10.1097/CEJ.0000000000000183] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
86 Reddavid R, Dagatti S, Franco C, Puca L, Tomatis M, Corso S, Giordano S, Degiuli M. Molecularly Targeted Therapies for Gastric Cancer. State of the Art. Cancers (Basel) 2021;13:4094. [PMID: 34439248 DOI: 10.3390/cancers13164094] [Reference Citation Analysis]
87 Mawalla B, Yuan X, Luo X, Chalya PL. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes 2018;11:21. [PMID: 29329598 DOI: 10.1186/s13104-018-3137-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
88 Li M, Gao M, Xie X, Zhang Y, Ning J, Liu P, Gu K. MicroRNA-200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER-ERCC3/4 pathway. Oncol Lett 2019;18:145-52. [PMID: 31289483 DOI: 10.3892/ol.2019.10304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
89 Fajardo-puerta AB, Mato Prado M, Frampton AE, Jiao LR. Gene of the month: HGF. J Clin Pathol 2016;69:575-9. [DOI: 10.1136/jclinpath-2015-203575] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
90 Wang G, Sun J, Liu G, Fu Y, Zhang X. Bradykinin Promotes Cell Proliferation, Migration, Invasion, and Tumor Growth of Gastric Cancer Through ERK Signaling Pathway. J Cell Biochem 2017;118:4444-53. [PMID: 28464378 DOI: 10.1002/jcb.26100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
91 Obermannová R, Lordick F. Insights into next developments in advanced gastric cancer. Curr Opin Oncol 2016;28:367-75. [PMID: 27092990 DOI: 10.1097/CCO.0000000000000289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
92 Liu Y, Zhao J, Zhang W, Gan J, Hu C, Huang G, Zhang Y. lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci Rep 2015;5:10159. [PMID: 25959498 DOI: 10.1038/srep10159] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 16.3] [Reference Citation Analysis]
93 Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M. Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. Oncotarget 2018;9:22332-9. [PMID: 29854281 DOI: 10.18632/oncotarget.24900] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
94 Dai J, Qian C, Su M, Chen M, Chen J. Gastrokine-2 suppresses epithelial mesenchymal transition through PI3K/AKT/GSK3β signaling in gastric cancer. Tumor Biol 2016;37:12403-10. [DOI: 10.1007/s13277-016-5107-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
95 Roviello G, Polom K, Roviello F, Marrelli D, Multari AG, Paganini G, Pacifico C, Generali D. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. Cancer Invest 2017;35:187-94. [PMID: 28165839 DOI: 10.1080/07357907.2016.1276185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
96 Kanat O, O’Neil B, Shahda S. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015; 7(12): 401-410 [PMID: 26690491 DOI: 10.4251/wjgo.v7.i12.401] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
97 Lordick F. Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol. 2014;15:914-916. [PMID: 24965570 DOI: 10.1016/s1470-2045(14)70273-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
98 Moehler M, Mahlberg R, Heinemann V, Obermannová R, Kubala E, Melichar B, Weinmann A, Scigalla P, Tesařová M, Janda P, Hédouin-biville F, Mansoor W. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. Gastric Cancer 2017;20:358-67. [DOI: 10.1007/s10120-016-0618-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
99 Roviello G, Petrioli R, Marano L, Polom K, Marrelli D, Perrella A, Roviello F. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer 2016;19:31-41. [PMID: 26329368 DOI: 10.1007/s10120-015-0537-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
100 Chen WM, Chen WD, Jiang XM, Jia XF, Wang HM, Zhang QJ, Shu YQ, Zhao HB. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer. World J Gastroenterol 2017; 23(33): 6100-6110 [PMID: 28970725 DOI: 10.3748/wjg.v23.i33.6100] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
101 Mulder KE, Ahmed S, Davies JD, Doll CM, Dowden S, Gill S, Gordon V, Hebbard P, Lim H, McFadden A, McGhie JP, Park J, Wong R. Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol. 2016;23:425-434. [PMID: 28050139 DOI: 10.3747/co.23.3384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
102 Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A. Personalised Treatment in Gastric Cancer: Myth or Reality? Curr Oncol Rep. 2016;18:41. [PMID: 27215435 DOI: 10.1007/s11912-016-0525-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
103 Xie Y, Zhi X, Su H, Wang K, Yan Z, He N, Zhang J, Chen D, Cui D. A Novel Electrochemical Microfluidic Chip Combined with Multiple Biomarkers for Early Diagnosis of Gastric Cancer. Nanoscale Res Lett 2015;10:477. [PMID: 26659608 DOI: 10.1186/s11671-015-1153-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
104 Wang Y, Xiao H, Wang C, Wu H, He H, Yao C, Cui J, Li W. M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signaling pathways. J Cell Biochem 2020;121:2330-42. [PMID: 31692032 DOI: 10.1002/jcb.29456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
105 Wu W, Wei N, Shao G, Jiang C, Zhang S, Wang L. circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6. Onco Targets Ther 2019;12:8197-205. [PMID: 31632070 DOI: 10.2147/OTT.S193031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 Zhao J, Li H, Min L, Han X, Shu P, Yang Y, Gan Q, Wang X, Wang H, Ruan Y, Qin J, Sun Y, Qin X. High expression of tumor necrosis factor receptor-associated factor 2 promotes tumor metastasis and is associated with unfavorable prognosis in gastric cancer. J Gastroenterol Hepatol 2018;33:431-42. [PMID: 28482378 DOI: 10.1111/jgh.13818] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
107 Wu J, Qin W, Wang Y, Sadik A, Liu J, Wang Y, Song P, Wang X, Sun K, Zeng J, Wang L. SPDEF is overexpressed in gastric cancer and triggers cell proliferation by forming a positive regulation loop with FoxM1. J Cell Biochem 2018;119:9042-54. [PMID: 30076647 DOI: 10.1002/jcb.27161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
108 Messager M, de Steur W, Boelens P, Jensen L, Mariette C, Reynolds J, Osorio J, Pera M, Johansson J, Kołodziejczyk P, Roviello F, De Manzoni G, Mönig S, Allum W. Description and analysis of clinical pathways for oesophago-gastric adenocarcinoma, in 10 European countries (the EURECCA upper gastro intestinal group – European Registration of Cancer Care). European Journal of Surgical Oncology (EJSO) 2016;42:1432-47. [DOI: 10.1016/j.ejso.2016.01.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
109 Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med 2016;5:1444-53. [PMID: 27073068 DOI: 10.1002/cam4.720] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
110 Fornaro L, Vivaldi C, Lin D, Xue H, Falcone A, Wang Y, Crea F, Bootman MD. Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. PLoS One. 2017;12:e0182818. [PMID: 28846697 DOI: 10.1371/journal.pone.0182818] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
111 West AC, Tang K, Tye H, Yu L, Deng N, Najdovska M, Lin SJ, Balic JJ, Okochi-Takada E, McGuirk P, Keogh B, McCormack W, Bhathal PS, Reilly M, Oshima M, Ushijima T, Tan P, Jenkins BJ. Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer. Oncogene. 2017;36:5134-5144. [PMID: 28481875 DOI: 10.1038/onc.2017.121] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
112 Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654-2664. [PMID: 27156933 DOI: 10.1016/s0140-6736(16)30354-3] [Cited by in Crossref: 856] [Cited by in F6Publishing: 627] [Article Influence: 142.7] [Reference Citation Analysis]
113 Serrano OK, Love C, Goldman I, Huang K, Ng N, Abraham T, Da Silva R, Friedmann P, Libutti SK, Kennedy TJ. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review. J Surg Oncol. 2016;113:640-646. [PMID: 27115836 DOI: 10.1002/jso.24190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]